Nieuweboer AJ , Hu S , Gui C , Hagenbuch B , Ghobadi Moghaddam-Helmantel IM , Gibson AA , de Bruijn P , Mathijssen RH , Sparreboom A .

GM077336 NIGMS NIH HHS , P30 CA021765 NCI NIH HHS , P30CA021765 NCI NIH HHS , R01 GM077336 NIGMS NIH HHS , RR021940 NCRR NIH HHS , P20 GM103549 NIGMS NIH HHS

Ait-Oudhia, Meta-analysis of nanoparticulate paclitaxel delivery system pharmacokinetics and model prediction of associated neutropenia. 2012, Pubmed

Ait-Oudhia, Meta-analysis of nanoparticulate paclitaxel delivery system pharmacokinetics and model prediction of associated neutropenia. 2012, Pubmed
Desai, Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. 2006, Pubmed
Ellis, Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL. 1999, Pubmed
Engel, Pharmaceutical excipients influence the function of human uptake transporting proteins. 2012, Pubmed
Engels, Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel. 2006, Pubmed
Fahrmayr, Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. 2012, Pubmed
Fujita, Direct inhibition and down-regulation by uremic plasma components of hepatic uptake transporter for SN-38, an active metabolite of irinotecan, in humans. 2014, Pubmed
Gardner, Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. 2008, Pubmed
Gui, Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. 2008, Pubmed
Gui, Identification, Ki determination and CoMFA analysis of nuclear receptor ligands as competitive inhibitors of OATP1B1-mediated estradiol-17beta-glucuronide transport. 2009, Pubmed
Hennenfent, Novel formulations of taxanes: a review. Old wine in a new bottle? 2006, Pubmed
Henningsson, Mechanism-based pharmacokinetic model for paclitaxel. 2001, Pubmed
Iusuf, Functions of OATP1A and 1B transporters in vivo: insights from mouse models. 2012, Pubmed
Izquierdo, A phase I clinical and pharmacokinetic study of paclitaxel and docetaxel given in combination in patients with solid tumours. 2006, Pubmed
KALISS, Plasma and blood volumes of mouse organs, as determined with radioactive iodoproteins. 1950, Pubmed
König, Transporters and drug-drug interactions: important determinants of drug disposition and effects. 2013, Pubmed
Lancaster, Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics. 2013, Pubmed
Letschert, Molecular characterization and inhibition of amanitin uptake into human hepatocytes. 2006, Pubmed
Müller, Transporter-mediated drug-drug interactions. 2011, Pubmed
Neesse, SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice. 2014, Pubmed
Rochat, Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism. 2005, Pubmed
Roth, OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. 2012, Pubmed
Smith, Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. 2005, Pubmed , Xenbase
Smith, Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. 2007, Pubmed , Xenbase
Sparreboom, Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. 1996, Pubmed
Sparreboom, Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. 1997, Pubmed
Sparreboom, Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. 1999, Pubmed
Svoboda, Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: relevance for paclitaxel transport. 2011, Pubmed , Xenbase
Takano, Paclitaxel-resistance conferred by altered expression of efflux and influx transporters for paclitaxel in the human hepatoma cell line, HepG2. 2009, Pubmed
Tan, Current development in nanoformulations of docetaxel. 2012, Pubmed
Tanino, Organic anion transporting polypeptide 2-mediated uptake of paclitaxel and 2'-ethylcarbonate-linked paclitaxel in freshly isolated rat hepatocytes. 2009, Pubmed
Vrignaud, Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. 2013, Pubmed
Walker, Organic anion transporting polypeptide 1B transporters modulate hydroxyurea pharmacokinetics. 2013, Pubmed
Yamaguchi, Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. 2008, Pubmed
Yardley, nab-Paclitaxel mechanisms of action and delivery. 2013, Pubmed
Yeh, Formulating paclitaxel in nanoparticles alters its disposition. 2005, Pubmed
Zaher, Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin. 2008, Pubmed
Zhang, Paclitaxel drug delivery systems. 2013, Pubmed
Zolk, Transporter-mediated drug uptake and efflux: important determinants of adverse drug reactions. 2011, Pubmed
de Bruijn, The issue of non-specific binding of cabazitaxel. 2013, Pubmed
de Graan, Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. 2012, Pubmed
ten Tije, Pharmacological effects of formulation vehicles : implications for cancer chemotherapy. 2003, Pubmed
van Tellingen, Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice. 1999, Pubmed
van Tellingen, Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. 1999, Pubmed
van Zuylen, Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. 2001, Pubmed
van de Steeg, High impact of Oatp1a/1b transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel. 2011, Pubmed
van de Steeg, Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice. 2013, Pubmed